Printer Friendly

RHONE-POULENC RORER COMMENTS ON RECENT INTEREST IN PROGRESS ON AIDS IMMUNOTHERAPEUTICS IN CLINICAL STUDIES

      RHONE-POULENC RORER COMMENTS ON RECENT INTEREST IN PROGRESS
             ON AIDS IMMUNOTHERAPEUTICS IN CLINICAL STUDIES
    COLLEGEVILLE, Pa., Nov. 13 /PRNewswire/ -- Rhone-Poulenc Rorer (NYSE: RPR) commented today on the recent interest in progress on AIDS immunotherapeutics in clinical studies and on yesterday's FDA Advisory Committee meeting discussing surrogate end-points in AIDS therapies.
    In conjunction with Immune Response Corporation, RPR is conducting Phase II/III clinical trials on an AIDS therapeutic vaccine.  These double-blind, placebo-controlled studies began in September 1990 and are scheduled to conclude in late 1992.  To date, these and other studies indicate that the product appears safe and well tolerated.
    As RPR has previously stated, until these studies are completed, the company will not have any clear indication of whether or not the product appears to be effective in preventing the transition to AIDS in seropositive patients.  The studies are designed to capture changes in viral burden, T-cell counts and clinical end points.  Consistent with the opinions expressed in yesterday's FDA Advisory Committee meeting, all of these end-points should be considered in the evaluation and ultimate approval of immunotherapeutics.
    Rhone-Poulenc Rorer is a global pharmaceutical company dedicated to human health.  It operates in the following major therapeutic areas: cardiovascular, bone metabolism/rheumatology, gastroenterology, central nervous system and analgesia, anti-infectives, AIDS, cancer, hypersensitivity, and plasma derivatives.  RPR has annualized sales of more than $3.6 billion and an annualized investment in research of over $440 million.  The company operates in all major markets of the world.
    /delval/
    -0-                         11/13/91
    /CONTACT:  Rhone-Poulenc Rorer media relations, 215-454-3871, or investor relations, 215-454-3851/ CO:  Rhone-Poulenc Rorer Inc. ST:  Pennsylvania IN:  MTC SU: CC-JS -- PH017 -- 3904 11/13/91 11:35 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 13, 1991
Words:278
Previous Article:MICROCOM ANNOUNCES UPGATE -- NEW ON-LINE BULLETIN BOARD SERVICE FOR UTILITY PRODUCT GROUP; OFFERING MICROCOM USERS 24-HOURS ON-LINE SUPPORT
Next Article:CANADA NEWSWIRE AVAILABLE ONLINE IN DIALOG'S FILE 613
Topics:


Related Articles
THE IMMUNE RESPONSE CORPORATION COMMENTS ON INTEREST IN PROGRESS ON HIV THERAPEUTIC VACCINE
THE IMMUNE RESPONSE CORP., RHONE-POULENC RORER INC. AND PASTEUR MERIEUX CONNAUGHT GROUP ANNOUNCE DISCUSSIONS ON HIV MANUFACTURING JOINT VENTURE
RHONE-POULENC RORER APPOINTS NEW PRESIDENT OF RESEARCH AND DEVELOPMENT
WARNER-LAMBERT, RHONE-POULENC RORER AGREE TO CO-DEVELOP AND CO-PROMOTE ADVANCED QUINOLONE ANTIBACTERIAL IN U.S. AND CANADA
WARNER-LAMBERT, RHONE-POULENC RORER AGREE TO CO-DEVELOP AND CO-PROMOTE ADVANCED QUINOLONE ANTIBACTERIAL IN U.S. AND CANADA
THE IMMUNE RESPONSE CORPORATION AND RHONE-POULENC RORER INC. COMMIT $18 MILLION ADDITIONAL FUNDING FOR AIDS JOINT VENTURE
THE IMMUNE RESPONSE CORP., RHONE-POULENC RORER INC. ANNOUNCE PRELIMINARY EVALUATION OF HIV THERAPEUTIC VACCINE DOSE-RANGING CLINICAL TRIAL
THE IMMUNE RESPONSE CORPORATION AND RHONE-POULENC RORER INC. COMMENCE ARBITRATION
RHONE-POULENC RORER FILES DEMAND FOR ARBITRATION IN ST. LOUIS, MISSOURI
New Indication for Granocyte(R) Will Enable European Cancer Patients To Avoid Bone Marrow Transplantation

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters